Learn more about the motivations behind Cadence’s new Arm-based system chiplet in the latest installment of The Briefing.
Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback